헌팅턴병 시장

Huntington's Disease Market Size, Share, Growth Demand Overview
Huntington’s Disease Market size was valued at USD 362.0 million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 38.7% during the forecast period (2023-2030). Huntington's disease is an inherited disease that causes the degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on the functional abilities of humans and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in their age of 30 to 40. When the disease begins before age 20, the condition is known as juvenile Huntington's disease. Both men and women are susceptible to this disease. It is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms.
As per DataM Intelligence, Huntington’s Disease Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Huntington’s Disease Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Huntington’s Disease Market in the United States and Canada produces the utmost share. Whereas the European Huntington’s Disease Market is projected to continue its presence globally during the period of 2022- 2029.
Huntington's Disease Market Report Scope
Metrics Details
Market CAGR 38.7%
Segments Covered By Product Type, By Distribution Channel, and By Region
Report Insights Covered Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region Asia Pacific
Largest Market Share North America
To get a Free sample click here
Huntington's Disease Market Growth Drivers, and Opportunities
In recent time, unmet medical need is key driver of the global Huntington’s disease therapeutics market. Increased pharmaceutical R&D investment and introduction of innovative drugs are increasing the growth of global Huntington’s disease market.
The increasing R&D investments and technological innovations in Huntington’s disease therapies are expected to drive market growth.
Increased pharmaceutical R&D investment and introduction of innovative drugs have also fuel the growth of global Huntington’s disease therapeutics market. This is due to small number of curative drugs has led manufacturers to increase investment in R&D for development of innovative solutions to treat Huntington’s disease.
Extensive pipeline drugs with properties, such as high patient compliance and improved safety, is also supporting in the growth of global Huntington’s disease therapeutics market. Alternative therapies, such as psychotherapy, speech therapy and physiotherapy hold immense potential to the growth of global Huntington’s disease therapeutics market.
Currently, only two symptom-alleviating therapies are specifically approved for HD: Xenazine and Austedo. The market is witnessing a shift in terms of a drug-development approach from conventional symptomatic therapies to disease-modifying therapies, driven by a better understanding of the pathogenesis of this disorder. Rapid uptake of improved symptomatic therapies and pipeline breakthroughs will remain the major factor driving the market over the next few years.
Depression associated with Huntington’s Disease is expected to hamper the market growth.
The clinical depression associated with Huntington's disease may increase the risk of suicide. Some research suggests that the greater risk of suicide occurs before a diagnosis is made and in middle stages of the disease when a person has begun to lose independence. Eventually, a person with Huntington's disease requires help with all activities of daily living and care. Late in the disease, he or she will likely be confined to a bed and unable to speak. However, a person's understanding of surroundings and interactions remain intact for a long time.
Industry Analysis
The global Huntington’s Disease market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Unmet Needs, Product Type Innovations.
Huntington's Disease Market Segmentation Analysis
Product type segment is expected to hold the largest market share in global Huntington’s disease market
Huntington's disease Therapeutics market segment by type covers Antidopaminergics, Anticonvulsants, Antipsychotics and Antidepressants
Unusually high levels of dopamine are thought to cause chorea (involuntary jerking or writhing movements) in Huntington’s patients. Toward later stages of the disease, however, dopamine levels can drop notably. Unusually low dopamine levels ease chorea, but cause such Parkinson’s disease-like symptoms as akinesia, the loss of the ability to move muscles voluntarily.
Antidopaminergic agents are used to ease chorea symptoms, but may also accelerate disease progression by reducing dopamine’s action to below a critical level.
Xenazine (tetrabenazine) and Austedo (deutetrabenazine) are two antidopaminergic medications approved by the U. S. Food and Drug Administration (FDA) to treat symptoms of chorea in Huntington’s disease. They work by blocking VMAT proteins and dopamine receptors. Austedo’s chemical structure is similar to Xenazine, but it is more stable.
Antipsychotic agents with a therapeutic effect in Huntington’s disease also work through an antidopaminergic mechanism. Antipsychotic agents reduce chorea and may also ease psychiatric symptoms, behavioral disturbances, and cognitive difficulties in Huntington’s patients.
AbilityHaldol (haloperidol) is a conventional antipsychotic medication. It has been shown to improve chorea symptoms, but its use is known to carry a number of side effects. Second-generation antipsychotic medications, known as atypical antipsychotics, are thought to be better tolerated than conventional agents, with fewer Parkinson’s-like side effects. These medications may include Risperdal (risperidone), Zyprexa (olanzapine), Seroquel (quetiapine), Geodon (ziprasidone), and Abilify (aripiprazole). Most of these medications work through multiple mechanisms, and not just as antidopaminergic agents.
Huntington's Disease Market Geographical Analysis
North America region holds the largest market share in the global Huntington’s Disease market
Geographically, the global Huntington’s disease therapeutics market is distributed over North America, Europe, APAC, and Latin America. North America dominates the global market due to increased awareness about the disease. In the North America market, the U.S. holds the largest market share, followed by Canada. Most of the major key players such as Teva Pharmaceutical Industries, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Ionis Pharmaceuticals are based in North America makes this region the largest shareholder in the market.
Europe accounts for the second largest market globally. In Europe, countries such as France, Germany, the U.K., and Spain contribute major shares of the market. Increasing awareness about the disease along with growing infrastructure for scientific research is projected to lead to market establishment for Huntington’s disease therapeutics in other parts of the world such as China, India, Japan, Africa, Argentina, and Brazil.
Competitive Landscape
Key players contributing highest market shares include Teva Pharmaceutical Industries, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Lundbeck, Prana Biotechnology Ltd., Valeant Pharmaceuticals International Inc., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline, Auspex Pharmaceuticals, Ceregene Inc., SOM Biotech, Siena Biotech, Raptor Pharmaceutical, Palobiofarma, and Ipsen.
The U.S. Food and Drug Administration (FDA) has given fast track designation to AMT-130, uniQure’s gene therapy candidate for the treatment of Huntington’s disease.
AMT-130 is an experimental gene therapy designed to block production of the mutated form of the huntingtin (HTT) protein, the underlying cause of Huntington’s disease. It consists of a small portion of synthetic genetic material, called microRNA (miRNA), which binds to the RNA messenger molecule carrying the genetic information needed to make the huntingtin protein, marking it for elimination. As a result, the gene therapy prevents the production of a faulty HTT protein.
Global Huntington’s Disease Market – Key Companies to Watch
Ionis Pharmaceuticals, Inc.
Overview: Ionis Pharmaceuticals is biotechnology company that was founded in 1989 and is headquartered in Carlsbad, California. It discovers and develops RNA targeted therapeutics. There are total 3 approved medicines those are: Nusinersen, Inotersen, and Volanesorsen. And studies on various drugs are taking place in company such as tominersen for Huntington’s disease.
Product Type Portfolio:
IONIS HTT: This drug is antisense drug that is used for the treatment of Huntington’s disease. It minimizes production of Huntington protein and its various forms that gets mutated and cause Huntington’s disease.
Key Developments: In Jan 2022, Ionis Pharmaceuticals, Inc. announced about the designing of phase 2 trial by their partner Roche to assess tominersen in Huntington’s disease.
The global huntington’s disease market report would provide an access to an approx. 45+market data table, 40+figures and 180pages